Sanofi
LTGO

Sanofi’s Latigo Biotherapeutics LTGO Stock Holding History

Sanofi’s Portfolio LTGO Stock Details LTGO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$11.2M Buy
+672,778
New +$14.2M 1.78% 11

Other funds holding LTGO

Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $72.4B AUM 24.61% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
Cambridge Investment Research Advisors
Cambridge Investment Research Advisors Fairfield, Iowa $45.2B AUM 20.72% 1-Year Est. Return
Citigroup
Citigroup New York $308B AUM 40.94% 1-Year Est. Return
Jacobi Capital Management
Jacobi Capital Management Pittston, Pennsylvania $2.11B AUM 19.6% 1-Year Est. Return

Sanofi's LTGO Position: Q3 2026 in Review

Sanofi opened a new position in Latigo Biotherapeutics (LTGO) in Q3 2026: 672,778 shares worth $11.2M. The stake represents 1.78% of the portfolio and ranks #11 among its holdings.

6 funds tracked by Wall St. Rank hold LTGO as of Q3 2026.

  • Sanofi held 672,778 shares of Latigo Biotherapeutics worth $11.2M as of Q3 2026.
  • Latigo Biotherapeutics was a new Sanofi position in Q3 2026.
  • Latigo Biotherapeutics made up 1.78% of Sanofi's portfolio in Q3 2026, its #11 holding.
  • 6 funds tracked by Wall St. Rank held Latigo Biotherapeutics as of Q3 2026.

Based on Sanofi's 13F filing for Q3 2026, filed 5 Nov 2026.